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A prospective study examining the role of
myocardial Fibrosis in outcome following
mitral valve repair IN DEgenerative mitral
Regurgitation: rationale and design of the
mitral FINDER study
Boyang Liu1,2* , Nicola C. Edwards1,2, Desley A. H. Neal1, Christopher Weston2, Gerard Nash2, Nicolas Nikolaidis4,
Thomas Barker3, Ramesh Patel3, Moninder Bhabra1 and Richard P. Steeds1,2
Abstract
Background: The optimal management of chronic severe primary degenerative mitral regurgitation (MR) is to
repair the valve but identification of the optimal timing of surgery remains challenging. Current guidelines suggest
‘watchful waiting’ until the onset of symptoms or left ventricular (LV) dysfunction but these have been challenged
as promoting ‘rescue surgery’. Better predictors are required to inform decision-making in relation to the necessity
and timing of surgery. Chronic volume overload is a stimulus for adverse adaptive LV remodelling. Subclinical
reduction in LV strain before mitral repair predicts a fall in LV ejection fraction following surgery and is thought to
reflect the development of myocardial fibrosis in response to chronic volume overload. Myocardial fibrosis can be
detected non-invasively using cardiac magnetic resonance (CMR) imaging techniques as an expansion of the
extracellular volume (ECV).
Methods/design: This study investigates whether: 1) patients with above median ECV will have smaller reduction
in end-systolic volume index (as a measure of the degree of reverse LV remodelling) on CMR following mitral valve
repair, compared to those with below median ECV; and 2) higher ECV on CMR, validated through histology, adversely
impacts upon post-operative complications and symptomatic improvement following surgery.
This is a multi-centre, prospective, cross-sectional comparison of patients prior to and 9 months following surgery for
chronic severe primary degenerative MR. To establish the natural history of ECV in MR, an additional cohort of patients
with asymptomatic MR who do not wish to consider early repair will be followed. Investigations include CMR,
cardiopulmonary exercise test, stress echocardiography, signal-averaged electrocardiogram, 24-h electrocardiogram
monitoring, laboratory tests and patient-reported outcome measures. Patients undergoing surgery will have cardiac
biopsies performed at the time of mitral valve repair for histological quantification of fibrosis.
Discussion: This study will advance our understanding of ventricular remodelling in MR, its impact on patient
symptoms and ventricular response following surgery. Establishing the link between myocardial fibrosis (measured on
CMR and validated through histology), with early ventricular dysfunction, will offer physicians a novel non-invasive
biomarker that can further inform the timing of surgery.
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Background
Challenges in determining the optimal timing of surgery
Mitral regurgitation (MR) is the most common form of
valvular disease in the USA, affecting 2.5% of the general
population and over 10% of those aged 75 years and
older [1]. It is the second most frequent valve disease
requiring surgery in Europe, and the prevalence of
moderate-to-severe MR is expected to double by 2030
due to an ageing population [2]. Improvements in the
diagnosis, quantification and surgical techniques for
repair of a primary degenerative mitral valve (MV) now
allow restoration of normal life expectancy following
surgery [3].
Current AHA/ACC/ESC guidelines recommend ex-
pectant management until class 1 indications for surgery
are reached, namely development of NYHA II-IV symp-
toms; LV ejection fraction (LVEF) <60% or LV internal
diameter in systole ≥40 mm [4, 5]. Unfortunately, in
spite of clear guidelines on the timing of surgery, a fifth
of patients with severe primary MR continue to present
post-operatively with reduced ejection fraction and an
increased risk of congestive cardiac failure [6] despite
single surgeon [7] and single centre [8] studies suggest-
ing that better outcomes may be achieved. Class IIa indi-
cations for (MV) repair in asymptomatic patients at low
surgical risk are also widely followed, although there is
evidence for this from only one randomised study [9].
Proponents for earlier surgery make reference to registry
data showing that repair in asymptomatic MR may result
in better LV function, lower rates of heart failure and
stroke [10], and normal life expectancy [7].
Careful surveillance with surgery delayed until class 1
indications are met, however, may deliver outcomes that
are equally as good as early MV repair. In a study of 132
consecutive patients, a programme of regular (3–12
monthly) review with referral based on Class 1 indica-
tions delivered survival rates equivalent to the general
population, both in those proceeding with surgery and
in those who were managed conservatively; 55 ± 6%
avoided surgery altogether at 8 years without comprom-
ising their outcome [11]. Since primary MR increases in
prevalence with age and given the ageing of the popula-
tion in Europe, there are likely to be increasing numbers
of patients who may wish to avoid surgery while they
feel well, providing their long-term outcome is not com-
promised. Moreover, there is the potential for problems
with an approach that pushes asymptomatic patients
through major cardiothoracic surgery in the absence of
randomised trial evidence. Firstly, by definition, surgery
cannot improve quality of life if the individual is truly
asymptomatic but does commit the patient to a period
of rehabilitation and is associated with a minimum
mortality risk of 1%. Secondly, the ability to identify a
reparable MV is imperfect and not everyone who
expects a repair receives one. In the UK, only 64.6% of
patients undergo repair but in the study by Kang et al.
which recruited only those with ‘reparable’ valves, 6%
still ended up with replacement [9]. Operative mortality
in those planned for repair but ultimately requiring re-
placement is high. Finally, although MV repair is usually
successful and long-lasting, this is not always the case
(reoperation rate of 11–28% at 15 years) with one third
having a late recurrence of moderate or severe MR [12].
In the absence of large-scale randomised data, debate
continues [13, 14].
Ventricular remodelling to guide the timing of surgery
Whilst patients may possess the same degree of MR for
a similar duration, their ventricular function and
symptom status may be quite different, suggesting that
differential ventricular remodelling may be a potential
underlying factor that influences the onset of surgical in-
dications. In contrast to the traditional concept that
there is a transition point from ‘compensated’ to ‘decom-
pensated’ chronic primary MR, there is strong evidence
that left ventricular (LV) remodelling is progressive from
the earliest stages of MR with a reduction in early
myocardial velocity and global strain [15, 16]. This sub-
clinical reduction in contractility is in turn reflected in
LA dilatation due to elevated LV end-diastolic pressure
[17] and progressive secondary right ventricular failure
[18]. Sub-clinical LV dysfunction is measured through
change in strain via a number of methodologies, includ-
ing tissue Doppler, speckle tracking echocardiography
and feature-tracking CMR (FT-CMR), and predicts both
the onset of symptoms [16] and the degree of reverse LV
remodelling following MV repair [19]. Sub-clinical
changes in LV systolic deformation, impaired diastolic
relaxation and elevated LA pressure are frequently
ascribed to the presence of interstitial fibrosis [20], with
autopsy studies confirming that this develops in patients
with MR of varying degrees of severity [21].
Characterising change in myocardial contractility in
MR by fall in ejection fraction, increase in linear
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dimension and volume, or change in strain, whether
using echocardiography or CMR, is difficult because all
these techniques are volume-dependent. The evolution
of CMR T1 mapping techniques offers a completely dif-
ferent approach that is non-invasive, quantitative but is
not dependent on chamber size or volume status, since
the aim is to identify interstitial myocardial fibrosis as a
marker of ‘myocardial stress’ in MR [22]. T1 mapping
has been validated against histology as a method for
measuring interstitial fibrosis mainly in aortic stenosis,
inherited cardiomyopathies and all-cause heart failure
[23–25] with increasing T1 and ECV associated with in-
creased morbidity and mortality [26, 27]. Sequences
allow construction of parametric pixel-wise colour T1
map to quantitatively measure the longitudinal myocar-
dial relaxation time before and after gadolinium contrast
administration for measurement of T1 times and calcu-
lation of myocardial ECV. Using this technique, a strong
linear correlation has been demonstrated between ECV
and histological collagen volume fraction measured in
aortic stenosis and explanted hearts of patients undergo-
ing heart transplantation [28]. In a pilot study of 24
patients (mean age 62 +/− 16 years) with primary degen-
erative moderate or severe asymptomatic MR with no
class I indication for surgery, we previously found a
significant increase in ECV compared to age and gender-
matched controls [29]. The extent of fibrosis correlated
both with exercise capacity and a reduction in longitu-
dinal strain.
Therefore, this study aims to assess whether left ven-
tricular fibrosis as measured through CMR impacts
upon patient outcomes including ventricular recovery
following surgery, post-operative complications and
symptomatic improvement. The primary endpoint of
this study is the reduction in end-systolic volume index
on CMR (as a measure of reverse LV remodelling) at
9 months following surgery, comparing those with ECV
measured pre-operatively above and below the median.
The reduction in left ventricular end-systolic volume
index (LVESVi) is a commonly measured outcome par-
ameter for the quantification of reverse left ventricular
remodelling in MR [9, 30]. Secondary end-points
(Table 2) assess the difference in exercise performance,
symptom status, post-operative recovery and ventricular
contractility (measured by LVEF and myocardial strain)
between patients with an above and below-median ECV
before and 9 months after MV surgery.
Methods/design
Study design
This is a multicentre prospective, cross-sectional com-
parison of patients with primary degenerative MR before
and after MV repair. To establish the natural history of
ECV in MR, an additional cohort of patients with
asymptomatic MR who are not eligible or do not wish to
consider early MV repair (via a class IIa surgical indica-
tion) will be followed. Study design is illustrated in Fig. 1;
details of the inclusion and exclusion criteria and the
study endpoints are detailed in Tables 1 and 2
respectively.
The surgical centres participating in the trial will be
the University Hospital Birmingham NHS Foundation
Trust, University Hospitals Coventry and Warwickshire
NHS Trust, and The Royal Wolverhampton NHS Trust.
Baseline studies
Cardiac magnetic resonance imaging
All patients will undergo 1.5 T multiparametric CMR at
the University Hospital Birmingham site (1.5 Tesla
scanner Magnetom Avanto, Siemens). Vertical long axis
(VLA) and horizontal long axis (HLA) SSFP cine im-
aging (retrospective electrocardiographic gating, SSFP)
of the left and right ventricles are performed. These
images will be used to pilot the LV short axis stack ac-
quired using serial contiguous short axis cines (typical
parameters to be achieved: resolution 40–50 msec, repe-
tition time 3.2 msec, echo time 1.7 msec, flip angle 60,
field of view 300 mm, in-plane resolution 1.5 × 1.5 mm2,
slice thickness 7 mm with 3 mm gap, minimum 25
phases per cardiac cycle) in accordance with previously
validated methodology [31]. MV anatomy will be
assessed using dedicated planes traversing the A1/P1
A2/P2 and A3/P3 scallops of the MV.
Analysis of ventricular function, volume and LV mass
will be performed offline with delineation of papillary
muscles and trabeculations using thresholding (cvi42®
version 5.3.4, Circle Cardiovascular Imaging, Canada).
Measurements will be made off-line using the contigu-
ous short axis multi-slice acquisition with delineation of
atria/ventricles confirmed in matched long axis planes
[31]. For ventricular volume analysis, the endocardial
border will be detected and the largest and smallest cav-
ity volumes are defined as end-diastole and end-systole
respectively. The endocardial border is defined as the
boundary between blood pool and myocardium, with
papillary muscles excluded from volumes. Mitral regur-
gitant volume (MRV) will be calculated as the difference
between LV stroke volume (LVSV) and the aortic for-
ward stroke volume (AoSV). Regurgitant fraction (RF)
will be calculated as RF (%) = (MRV/LVSV) × 100.
Myocardial deformation will be assessed using 3D
feature-tracking on CMR (FT-CMR) using cvi42®
(version 5.3.4, Circle Cardiovascular Imaging, Canada).
3D FT-CMR will be performed using smoothed endocar-
dial and epicardial borders in the end-diastolic frame of
all short and long axis slices before defining the superior
RV insertion points within the LV. Peak systolic strain,
early diastolic strain rate and late diastolic strain rate
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will be recorded in the circumferential, radial and longi-
tudinal directions.
For myocardial characterisation, myocardial and blood
relaxation times pre- and 15 min after gadolinium
contrast administration will be measured offline to
calculate T1 times and ECV using cvi42® software as per
European Society of Cardiology consensus statement
[32]. All T1 maps will be checked for the presence of
breathing, susceptibility and gating related artefacts. To
Fig. 1 Study design flowchart
Table 1 Inclusion and exclusion criteria
Inclusion criteria
Age 18 and over
Primary degenerative mitral regurgitation (diagnosed and quantified
according to the European Association of Echocardiography
guidelines)
Exclusion criteria
Secondary mitral regurgitation
Primary mitral regurgitation not due to degenerative disease
(including rheumatic disease)
Co-existing moderate or severe aortic valve disease
Congenital heart disease
Inherited or acquired cardiomyopathy
Non-incidental or symptomatic coronary artery disease
Uncontrolled atrial fibrillation (resting heart rate > 100/min)
Pregnancy
Unable to undergo CMR
Unable to undergo cardiopulmonary exercise test
Table 2 Primary and secondary study end points
Primary end point
Change in end-systolic volume index on CMR (as a measure of reverse
LV remodelling)
Secondary end points
Exercise capacity assessed by peak VO2 using treadmill or bicycle
Health related quality of life assessed using the functional domain of
SF-36
Extracellular volume on CMR
Ejection fraction and global myocardial strain on CMR
Measures of surgical outcome including inotrope and IABP usage,
time to extubation, ITU and hospital length of stay, post-operative
weight gain (pre-op to post-op day 4)
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avoid the blood-myocardial boundary, 20% offset both
from the epicardial and endocardial borders will be
employed and care taken to avoid any areas of LGE.
Extracellular volume will be calculated using myocardial
and blood T1 values before and after contrast using vali-
dated formulae [33], ECV = λ * (1 – haematocrit), where:
λ ¼
1
T1myo post
− 1T1myo pre
1
T1blood post
− 1T1blood pre
Haematocrit for ECV calculation is be measured con-
temporaneously with the CMR study.
Cardiopulmonary exercise test
Patients will undergo cardiopulmonary exercise testing
(CPET) on a treadmill using an incremental RAMP
protocol based on American Thoracic Society guidelines
[34]. A RAMP slope, based on gender, age, and estimated
physical fitness of the subject will be set to obtain a test of
approximately 10 min duration. Subjects will wear a tight
facemask to permit continuous measurements of ventila-
tion, oxygen consumption (VO2), and carbon dioxide
production (VCO2) in expired gas, from which estimates
of peak oxygen consumption (peak VO2) and anaer-
obic threshold (AT) can be obtained using a V-slope
method [35].
Transthoracic echocardiography
Transthoracic echocardiography will be performed by
experienced echocardiographers accredited through the
British Society of Echocardiography (BSE). LV and right
ventricular (RV) dimensions, atrial dimensions, systolic
and diastolic function will be assessed according to the
requirements for the performance of a standard trans-
thoracic echocardiogram according to BSE guidelines
[36]. Estimated pulmonary artery systolic pressure will
be derived from the regurgitant jet of tricuspid regurgi-
tation calculated by the modified Bernoulli equation and
allowance made for right atrial pressure. Myocardial
tissue velocity and deformation will be assessed using
2D speckle tracking [37].
Stress echocardiography
Stress echocardiography will be carried out at the base-
line visit according to previously described methods
[38], but in brief, semi-supine bicycle ergometry will be
performed initially at workloads of 20-25 W for 2 min,
then increased in steps of 15-30 W every 2 min as
decided according to the physical fitness and symptom
status of the patient. During each 2-min interval, MR
quantification and estimations of LV filling pressure and
pulmonary artery pressure are performed (Epic, Phillips).
LV size and systolic function are assessed at baseline and
peak exercise. Global longitudinal strain will be derived
from the apical 2–3- and 4-chamber views via speckle
tracking at baseline and peak exercise. The quantifica-
tion of MR will be carried out using the integration of
quantitative and qualitative approaches [39]; ‘quantita-
tively’ by subtracting the stroke volume across the left
ventricular outflow tract (LVOT) from the stroke vol-
ume across the MV annulus, or the flow convergence
method by proximal isovelocity surface area; and ‘quali-
tatively’ by visual assessment of the colour flow jet area
and flow convergence zone.
Electrocardiogram
A standard 12 lead electrocardiogram (ECG) will be
performed for the assessment of baseline heart rate,
rhythm, and QRS morphology, followed by signal-
averaged ECG (SA-ECG) for the assessment of ventricu-
lar late potentials in those with sinus rhythm. SA-ECG
will be performed by averaging 250 beats using a
MAC® 5500 system (GE Healthcare, Illinois, U.S.A.) at
a filter setting of 40-250 Hz and aiming for a noise
level of <0.3 μV.
24-h Holter monitoring
3-channel 24-h Holter ECG recordings will be carried
out using Lifecard CF monitors (Spacelabs Healthcare,
Snoqualmie, U.S.A.). Holter data will be independently
analysed at University Hospital Birmingham using Path-
finder SL software (Spacelabs Healthcare, Snoqualmie,
U.S.A.). Supra-ventricular and ventricular ectopic bur-
den, as well as the type and frequency of arrhythmic
events, will be recorded. Time-domain analyses will be
recorded from automated measurements of heart rate
variability (HRV). Maximum, mean and minimum QT
and QTc duration from automated software assisted
analyses will be recorded according to previously estab-
lished methodology [40].
Laboratory tests and biomarkers
All patients will undergo routine blood tests for full
blood count, urea and electrolytes, liver function tests, C
reactive protein, N-terminal pro-B natriuretic peptide,
and high-sensitivity troponin T (lower limit of detection
5 ng/L, Roche) at the baseline and follow-up visits.
Blood tests will be carried out at the Clinical Biochem-
ical services at University Hospital Birmingham.
At initial visit, serum samples will also be stored for
the measurement of collagen turnover markers including
the amino terminal of type I and type III procollagen,
circulating levels of matrix metalloproteinase-1 and tis-
sue inhibitor of metalloproteinase-1 using commercially
available ELISA assays.
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Histology
Intraoperative myocardial biopsies (Tru-Cut biopsy
needle) will be taken from the LV septum, anterior and
posterior LV free wall. Samples will be fixed immediately
in 10% buffered formalin, embedded in paraffin, and
sections will be stained with Elastic Van Gieson (EHVG)
for assessment of myocardial fibrosis. The EHVG stains
fibrous tissue pink, elastic tissue purple and the muscle
brown. Digital images (300dpi x 300dpi resolution,
image size 1280 × 960 pixels) of the whole EHVG stained
slide at 4× objective magnification (12 per biopsy) will
be taken and analysed using Image J software (version
1.50i, National Institutes of Health, Bethesda, USA) by a
specialist cardiac histopathologist, blinded to the im-
aging findings. The area of the tissue and the area of fi-
brosis will be determined by manually drawing around
the outline of the tissue, and each area of pink/purple fi-
brosis using the surface pen on a surface book tablet.
Measurements will be given in pixels and the percent
fibrosis can be calculated.
Patient reported outcome symptom status
Subjects will be asked to provide data at entry and at
9 months post-surgery or post-first surveillance using a
self-completion questionnaire (SF-36 and Minnesota
Living with Heart Failure (MLWHF)) to eliminate any
observer bias. The SF-36 has established validity in
measurement of functional status in patients undergoing
MV repair [41] but the MLWHF and SF-36 emotional
score will also be collected for exploratory analysis to
inform larger studies.
Subject withdrawal
Patients may withdraw consent from the study at any
time. If the withdrawal is initiated by a healthcare
professional, full details for the reason for withdrawal is
recorded on the case report forms. In all other cases, a
simple statement reflecting patient preference is noted.
Planned statistical analysis
All analyses will be carried out on an intention to treat
basis. For all tests, summary statistics will be reported
and 95% confidence intervals will be constructed where
appropriate. A P value of <0.05 will be considered
statistically significant without adjustment for multiple
testing. Analyses will also be performed according to the
following subgroups: severity of MR, degree of ven-
tricular function as measured with above- and below-
median global myocardial strain, presence or absence of
subjective symptoms, and peak VO2 of ≥80% or <80%
on CPET.
Power calculation
Applying in-house pilot data and informed by previous
CMR studies [42], we expect the standard deviation of
LV end-systolic volume indexed to body surface area
(ESVi) will be 12 ml/m2. A survival advantage has previ-
ously been shown with a 7 ml/m2 difference in ESVi
from pre- to post-surgery in patients with asymptomatic
MR [9]. This change has been selected as a clinically-
significant difference for the study; hence it is powered
on a comparison of the change in ESVi between two
groups: those above and below median ECV. An inde-
pendent samples t-test with 48 patients per group (96
total) and a within-group standard deviation of 12 ml/
m2 yield a minimum detectable difference of 7 ml/m2 at
80% power, with alpha = 0.05. We therefore plan to
recruit 115 subjects allowing for a 15% drop-out rate.
Monitoring and safety assessments
Interventions in this study will be carried out according
to the decision of the clinician responsible for the
patient and are therefore independent of the study itself.
Therefore, there is no formal data monitoring
committee.
Discussion
Physicians and patients with asymptomatic severe pri-
mary degenerative MR are faced with a significant con-
undrum. Delaying surgery until the onset of a class I
surgical indication is associated with a possible outcome
penalty for the patient [43]. Yet it is also difficult to ad-
vocate early surgery in the asymptomatic, elderly patient,
when watchful-waiting offers a reasonable probability of
remaining symptom-free for potentially the remainder of
the patient’s life without penalty if an operation becomes
necessary [11]. There is a clear unmet need for objective
and quantitative markers of LV disease that can contrib-
ute to the decision regarding the optimal time for MV
surgery.
The Mitral FINDER study aims to identify why pa-
tients with the same severity of MR can have such wide-
range of symptoms before, and difference in ventricular
response after surgery. By improving our understanding
of ventricular remodelling in MR, and establishing the
relationship between myocardial fibrosis and early ven-
tricular dysfunction, this study will offer physicians a
novel non-invasive biomarker that can further inform
the timing of surgery. Measuring myocardial T1 relax-
ation offers a quantitative method of assessing ventricu-
lar fibrosis in primary MR that is not dependent on
chamber volume and is not therefore subject to the limi-
tations of ejection fraction in volume overload. This
non-invasively measured imaging biomarker of fibrosis
will be validated on myocardial biopsy performed at the
time of MV repair. It is central to the hypothesis that
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patients with more myocardial fibrosis are at risk of sub-
clinical myocardial dysfunction, followed by subjective
exercise intolerance, that ultimately leads to overt car-
diac dysfunction and irreversible myocardial damage
that manifests as impaired reverse LV remodelling. We
propose that in a population of patients with severe
primary degenerative MR, without a class I indication
for surgery, the presence of interstitial fibrosis as
assessed by higher myocardial T1 / ECV values will
identify patients with an increased risk of LV dysfunction
after surgery. If this is shown, then there may be a role
for routine use of CMR to risk stratify patients who
would truly benefit from “early” surgery. It would also
provide a rationale for larger clinical trials designed to
examine cardiovascular morbidity and mortality end-
points, as well as the use of anti-fibrotic treatments such
as spironolactone to reverse or delay LV fibrosis in
asymptomatic severe MR.
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